RIPK1 Inhibitor Therapy in Neurodegeneration

RIPK1 Inhibitor Therapy in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Inhibitor Therapy in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Necrostatin-1s</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Deguelin</td>
<td>RIPK1/PI3K</td>
</tr>
<tr>
<td class="label">DQP</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>Psoriasis</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>IBD</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>RA</td>
</tr>
</table>

Receptor-Interacting Protein Kinase 1 (RIPK1) is a critical regulator of necroptosis, a form of programmed cell death that contributes to neuronal loss in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and other neurodegenerative disorders[@galluzzi2022][@yuan2021]. RIPK1 sits at the intersection of cell death and inflammatory signaling, making it an attractive therapeutic target for neurodegeneration where both processes arepathologically elevated[@wang2022].

RIPK1 Inhibitor Therapy in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">RIPK1 Inhibitor Therapy in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Necrostatin-1s</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Deguelin</td>
<td>RIPK1/PI3K</td>
</tr>
<tr>
<td class="label">DQP</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>Psoriasis</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>IBD</td>
</tr>
<tr>
<td class="label">GSK-2982772</td>
<td>RA</td>
</tr>
</table>

Receptor-Interacting Protein Kinase 1 (RIPK1) is a critical regulator of necroptosis, a form of programmed cell death that contributes to neuronal loss in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and other neurodegenerative disorders[@galluzzi2022][@yuan2021]. RIPK1 sits at the intersection of cell death and inflammatory signaling, making it an attractive therapeutic target for neurodegeneration where both processes arepathologically elevated[@wang2022].

Necroptosis is a caspase-independent cell death mechanism that involves RIPK1-mediated activation of RIPK3 and MLKL, leading to plasma membrane rupture and release of intracellular inflammatory contents. In neurodegenerative diseases, chronic neuroinflammation triggers necroptotic pathways in neurons and glia, contributing to progressive neuronal loss[@kourtis2023].

This page covers RIPK1 biology, necroptosis mechanism, therapeutic inhibitors, evidence across neurodegenerative diseases, clinical trial status, and future directions.

RIPK1 and Necroptosis Biology

The Necroptosis Pathway

Necroptosis is activated by death receptor ligation (TNF-α, FasL, TRAIL) when caspase-8 activity is inhibited. The pathway involves:

RIPK1 Structure and Function

RIPK1 is a serine/threonine kinase with multiple functional domains:

• N-terminal kinase domain: Catalytic activity, target of inhibitors
• Intermediate domain: RIPK3 interaction
• C-terminal death domain: Death receptor interaction

• Kinase activity: Drives necroptosis when activated
• Scaffold function: Can promote apoptosis independently of kinase activity
• Inflammatory signaling: Activates NF-κB and MAPK pathways

RIPK1 in Neurodegeneration

RIPK1 activation in neurodegenerative diseases occurs through:

Evidence from postmortem brain:

• RIPK1 elevation in AD hippocampus (correlates with tau)[@zhu2023]
• RIPK1 in PD substantia nigra dopaminergic neurons[@iannaro2022]
• RIPK1 activation in ALS motor cortex and spinal cord[@liu2022]
• RIPK1 in HD striatum and cortex

RIPK1 Inhibitors

Drug Candidates

1. Necrostatin-1 (Nec-1)

• Mechanism: Allosteric RIPK1 kinase inhibitor
• Status: Research use, not clinically approved
• Evidence:
• First discovered in 2005 as necroptosis inhibitor
• Neuroprotective in multiple animal models
• Limited brain penetration
• Used extensively in research

• Mechanism: Stabilized analog of Nec-1
• Status: Research compound
• Advantages:
• Improved metabolic stability
• Better solubility
• Used in advanced preclinical studies

• Mechanism: Natural product, RIPK1 inhibitor (also inhibits PI3K)
• Status: Investigational
• Evidence:
• Neuroprotective in PD models[@lee2021]
• Anti-inflammatory properties
• Cancer chemopreventive agent
• Limited by off-target effects

• Mechanism: RIPK1 kinase inhibitor
• Status: Preclinical development
• Advantages:
• Brain-penetrant
• Orally bioavailable
• Improved selectivity

• Mechanism: Selective RIPK1 inhibitor
• Status: Clinical development (Phase 1/2)
• Evidence:
• First RIPK1 inhibitor in clinical trials
• Tested in psoriasis, IBD, RA
• Safety profile established
• Potential for CNS applications

• Mechanism: RIPK1 inhibitor
• Status: Preclinical
• Note: Developed for inflammatory diseases

Mechanism of Neuroprotection

RIPK1 inhibitors protect neurons through:

• Direct necroptosis blockade: Prevent MLKL activation and membrane permeabilization
• Anti-inflammatory effects: Reduce TNF-α-mediated inflammation
• Anti-apoptotic effects: Can inhibit caspase-dependent cell death
• Microglial modulation: Reduce inflammatory microglial activation

Evidence by Disease

Amyotrophic Lateral Sclerosis

Evidence:

• Strong evidence for RIPK1 involvement in ALS[@liu2022]
• TNF-α levels elevated in ALS CSF and brain
• RIPK1 activation in motor neurons and glia
• Postmortem ALS tissue shows RIPK1 and p-MLKL positivity
• Correlates with disease severity

• Motor neurons are susceptible to necroptosis
• Neuroinflammation drives disease progression
• Targeting both cell death and inflammation

• Nec-1 extends survival in ALS mouse models
• Deguelin improves motor function
• RIPK1 inhibitors reduce motor neuron loss
• Combined with SOD1-targeted approaches

• GSK-2982772 Phase 1/2 completed (non-neurological indications)
• No ALS-specific trials yet
• Strong biological rationale for development

Alzheimer's Disease

Evidence:

• RIPK1 elevation in AD brain[@zhu2023]
• Co-localization with tau pathology
• TNF-α elevation in AD brain and CSF
• RIPK1 in microglia surrounding plaques
• Correlates with cognitive decline

• Chronic neuroinflammation drives progression
• Neuronal loss involves necroptosis
• May preserve remaining neurons

• Nec-1 reduces neuronal loss in AD models
• Improves memory in amyloid models
• Reduces microglial activation
• Combined with anti-amyloid approaches

• No AD-specific trials yet
• Target validation from human tissue
• Potential for disease modification

Parkinson's Disease

Evidence:

• RIPK1 in PD substantia nigra[@iannaro2022]
• TNF-α elevation in PD brain and CSF
• α-Synuclein triggers necroptosis pathway
• Postmortem tissue shows RIPK3 activation

• Dopaminergic neurons vulnerable to necroptosis
• Neuroinflammation is central to PD pathogenesis
• May protect remaining neurons

• Deguelin protects dopaminergic neurons[@lee2021]
• Nec-1 in MPTP model shows neuroprotection
• RIPK1 inhibitors reduce neuroinflammation
• Combined with LRRK2 inhibitors

• No PD-specific trials yet
• Strong preclinical rationale
• Good candidate for clinical development

Huntington's Disease

Evidence:

• Emerging evidence for necroptosis in HD[@ref]
• RIPK1 elevation in HD striatum
• Mutant huntingtin triggers neuroinflammation
• Elevated TNF-α in HD models and patients

• Striatal neurons are particularly vulnerable
• Protein stress triggers necroptosis
• May reduce both cell death and inflammation

• RIPK1 inhibitors show efficacy in HD models
• Improves behavioral outcomes
• Reduces mutant huntingtin toxicity

• No HD trials yet
• Emerging biological rationale
• May combine with gene-silencing

CBS/PSP/FTD

Evidence:

• Chronic neuroinflammation in 4R-tauopathies
• RIPK1 in PSP and CBD brain
• TDP-43 pathology triggers necroptosis in FTD
• Common inflammatory mechanisms

• Neuroinflammation is a shared mechanism
• May benefit multiple tauopathies
• Addresses both neuroinflammation and cell death

• RIPK1 inhibitors in tauopathy models
• Reduces neuroinflammation
• May improve motor and cognitive function

• No trials yet
• Biological plausibility supports investigation

Comparison of Approaches

Combination Strategies

RIPK1 inhibitors may be combined with:

Safety Considerations

Potential Risks

• Immunosuppression: RIPK1 inhibition may impair immune function
• Infection risk: Necroptosis is defense mechanism
• Liver toxicity: Some compounds affect hepatic function
• Tumor promotion: Theoretical cancer risk

Monitoring Requirements

• Immune function tests
• Liver function tests
• Neurological assessments
• Infection surveillance

Therapeutic Window

• Necroptosis inhibition may be safer than general apoptosis inhibition
• Partial inhibition may be sufficient for benefit
• Temporal targeting (early disease) may reduce risks

Clinical Trial Landscape

Active Studies

• GSK-2982772 in inflammatory diseases (Phase 2)
• DQP in preclinical development
• Other RIPK1 inhibitors in Phase 1

Completed Studies

Challenges

Future Directions

• Brain-penetrant RIPK1 inhibitors for CNS
• Biomarker development for patient selection
• Combination approaches
• Earlier intervention

Cross-References

Related Mechanisms

• [Necroptosis in Neurodegeneration](/mechanisms/necroptosis)
• [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)
• [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
• [Cell Death Pathways in Neurodegeneration](/mechanisms/cell-death-pathways)

Related Proteins

• [RIPK1 Protein](/proteins/ripk1)
• [RIPK3 Protein](/proteins/ripk3)
• [MLKL Protein](/proteins/mlkl)
• [TNF-α Protein](/proteins/tnf-alpha)

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)

Related Therapeutics

• [Necrostatin-1](/therapeutics/necrostatin-1)
• [Deguelin](/therapeutics/deguelin)
• [GSK-2982772](/therapeutics/gsk-2982772)

Summary

RIPK1 inhibitor therapy represents a promising approach to neurodegenerative disease treatment by targeting necroptosis, a form of programmed cell death that contributes to neuronal loss in ALS, AD, PD, HD, and other disorders. Multiple drug candidates including Necrostatin-1, Deguelin, DQP, and GSK-2982772 have demonstrated neuroprotective effects in preclinical models. While clinical trials in neurodegenerative diseases have not yet begun, the strong biological rationale and established safety profiles from inflammatory disease trials support development. The dual role of RIPK1 in both cell death and inflammation makes it an attractive target for combination approaches. Future directions include brain-penetrant inhibitors, biomarker-driven patient selection, and combination therapies.

References